An interventional study of DermaSensor in Skin Cancer, Basal Cell Cancer and Squamous Cell Carcinoma, sponsored by DermaSensor, Inc.. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by DermaSensor, Inc. · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.
Among the 2,049 studies in Melanoma with a site in United States, this one is the 226th largest by planned enrollment of the 1,749 interventional ones that give a count, is one of 51 that started in 2026, is one of 159 with no phase, reaches primary completion later than 318 of the 435 other live ones, and was the 2,048th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States
Ages up to 25
John Kirkwood · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,049 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 934 · Phase 2 907 · Phase 3 115 · Phase 4 11
First in 1991; this study’s year is marked. 51 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.
Median enrollment 37 across the 1,749 interventional studies, 156 across the 212 observational. Of the 1,481 that completed or were terminated, 598 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
800 of 2,049 have an industry lead sponsor. The 10 most frequent:
DermaSensor, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
DermaSensor, Inc. has 3 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
141 of the studies in Melanoma with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 141 to your calendar (.ics) → With an account.
Among the 2,049 studies in Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial evaluates whether primary care physician access to the DermaSensor device increases the proportion of patients with histopathology-confirmed skin cancer compared with physician standard clinical assessment alone. Participating physicians are randomized and outcomes are drawn from existing electronic health record data for up to 500,000 patient encounters.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
This study's planned enrollment of 200 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.
Browse Melanoma studies →DermaSensor, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Compared within Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Not actively practicing in primary care at a participating study site
Primary care clinics continuing routine assessment of skin lesions without access to the DermaSensor device.
Primary care clinics with access to the DermaSensor device as an adjunct to clinical assessment of skin lesions.
Device: DermaSensor
Handheld device used by primary care physicians as an adjunct to clinical assessment of skin lesions suggestive of skin cancer, per its labeling.
Proportion of patients with histopathology-confirmed skin cancer
Proportion of all patients seen by participating primary care physicians with a skin cancer (melanoma, basal cell carcinoma, or squamous cell carcinoma) confirmed by histopathology within 12 months of the initial visit, compared between device-aided and unaided physicians.
Time frame: Within 12 months of the initial primary care visit
Number needed to refer or biopsy (NNRB)
Proportion of biopsies returning a malignant result and proportion of dermatology referrals returning a malignant result, compared between device-aided and unaided physicians.
Time frame: Within 12 months of the initial primary care visit
Skin cancers identified after a Monitor result or non-referral decision
Skin cancers confirmed during follow-up after an initial device Monitor result or a non-referral/non-biopsy decision, with stage and severity characterized, compared between groups.
Time frame: Within 12 months of the initial primary care visit
Change in skin cancer detection rate among device physicians
Rate of change in skin cancer detection among physicians using the device, compared with the same physicians before device access, the unaided arm, and non-user physicians in the device arm.
Time frame: From pre-device baseline period through study completion
Time to biopsy or dermatologist evaluation and to treatment
Interval from initial primary care presentation to (1) biopsy or dermatologist evaluation and (2) treatment of the skin lesion, compared between groups.
Time frame: Within 12 months of the initial primary care visit
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.
Of 227 interventional studies with no phase under Melanoma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.